Exosome-Coated Prussian Blue Nanoparticles for Specific Targeting and Treatment of Glioblastoma
ACS Applied Materials & Interfaces · 2024
DOI: 10.1021/acsami.4c02364 ↗Kurz gefasst
Fachartikel in der Zeitschrift ACS Applied Materials & Interfaces, 2024. Verfasst von Meghan L Hill und 9 weiteren Autor:innen. Hauptthemen laut MEDLINE: Ferrocyanides, Glioblastoma, Exosomes, Nanoparticles. Die Arbeit wurde bisher 22-mal zitiert (Crossref) und nennt 70 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NICHD NIH HHS, National Institute of Child Health and Human Development, Michigan State University.
Abstract (Originalsprache)
Glioblastoma is one of the most aggressive and invasive types of brain cancer with a 5-year survival rate of 6.8%. With limited options, patients often have poor quality of life and are moved to palliative care after diagnosis. As a result, there is an extreme need for a novel theranostic method that allows for early diagnosis and noninvasive treatment as current peptide-based delivery standards may have off-target effects. Prussian Blue nanoparticles (PBNPs) have recently been investigated as photoacoustic imaging (PAI) and photothermal ablation agents. However, due to their inability to cross the blood-brain barrier (BBB), their use in glioblastoma treatment is limited. By utilizing a hybrid, biomimetic nanoparticle composed of a PBNP interior and a U-87 cancer cell-derived exosome coating (Exo:PB), we show tumor-specific targeting within the brain and selective thermal therapy potential due to the strong photoconversion abilities. Particle characterization was carried out and showed a complete coating around the PBNPs that contains exosome markers. In vitro cellular uptake patterns are similar to native U-87 exosomes and when exposed to an 808 nm laser, show localized cell death within the specified region. After intravenous injection of Exo:PB into subcutaneously implanted glioblastoma mice, they have shown effective targeting and eradication of tumor volume compared to PEG-coated PBNPs (PEG:PB). Through systemic administration of Exo:PB particles into orthotopic glioblastoma-bearing mice, the PBNP signal was detected in the brain tumor region through PAI. It was seen that Exo:PB had preferential tumor accumulation with less off-targeting compared to the RGD:PB control. Ex vivo analysis validated specific targeting with a direct overlay of Exo:PB with the tumor by both H&E staining and Ki67 labeling. Overall, we have developed a novel biomimetic material that can naturally cross the BBB and act as a theranostic agent for systemic targeting of glioblastoma tissue and photothermal therapeutic effect.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
ORCID-Profile: Panangattukara Prabhakaran Praveen Kumar, Taeho Kim
Förderung
- NICHD NIH HHS
- National Institute of Child Health and Human Development
- Michigan State University
- HFH+MSU Health Sciences
Zitieren
APA
Hill, M. L., Chung, S. J., Woo, H. J., Park, C. R., Hadrick, K., Nafiujjaman, M., Kumar, P. P. P., Mwangi, L., Parikh, R., & Kim, T. (2024). Exosome-Coated Prussian Blue Nanoparticles for Specific Targeting and Treatment of Glioblastoma. ACS Applied Materials & Interfaces. https://doi.org/10.1021/acsami.4c02364
Vancouver
Hill ML, Chung SJ, Woo HJ, Park CR, Hadrick K, Nafiujjaman M, et al. Exosome-Coated Prussian Blue Nanoparticles for Specific Targeting and Treatment of Glioblastoma. ACS Applied Materials & Interfaces. 2024. doi:10.1021/acsami.4c02364
BibTeX
@article{Hill2024,
author = {Hill, Meghan L and Chung, Seock-Jin and Woo, Hyun-Joo and Park, Cho Rong and Hadrick, Kay and Nafiujjaman, Md and Kumar, Panangattukara Prabhakaran Praveen and Mwangi, Leila and Parikh, Rachna and Kim, Taeho},
title = {Exosome-Coated Prussian Blue Nanoparticles for Specific Targeting and Treatment of Glioblastoma},
journal = {ACS Applied Materials & Interfaces},
year = {2024},
doi = {10.1021/acsami.4c02364}
}
EUVIMED